Related Experiment Video
Updated: Jul 19, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Ezetimibe/simvastatin single tablet versus rosuvastatin in patients with hypercholesterolemia
Insights
Combination therapy with ezetimibe/simvastatin effectively lowers low-density lipoprotein cholesterol (LDL-C) more than rosuvastatin monotherapy. This approach may be essential for reaching strict LDL-C targets recommended by recent guidelines.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Current guidelines advocate for stringent low-density lipoprotein cholesterol (LDL-C) targets (70-100 mg/dL).
- A new study evaluates ezetimibe/simvastatin combination therapy against rosuvastatin monotherapy for LDL-C reduction.
Discussion:
- High-dose statin monotherapy may present disadvantages, including potential statin-induced proteinuria.
- Combination therapy demonstrates superior efficacy in achieving target LDL-C levels compared to monotherapy.
Key Insights:
- Ezetimibe/simvastatin combination therapy is more effective than rosuvastatin monotherapy in achieving LDL-C goals.
- The study reinforces previous findings on the efficacy of combination lipid-lowering strategies.
Outlook:
- Combination therapy may become increasingly crucial for meeting current LDL-C treatment goals.
- Further research may explore optimal combination strategies and long-term outcomes.
Abstract:
Recent guidelines recommend strict goals for low density lipoprotein cholesterol (LDL-C) (70-100 mg/dL; 1.8-2.6 mmol/L). These goals were set following the publication of several trials. In the current issue of the journal, a study compares different doses of the combination tablet (ezetimibe/simvastatin) with statin monotherapy (rosuvastatin). In keeping with previous literature, the combination therapy was more effective in achieving LDL-C goals. This editorial comments on the potential disadvantages of using monotherapy with high-dose statins and considers the issue of statin-induced proteinuria. Combination therapy may need to be increasingly used to achieve the LDL-C targets set by recent guidelines.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis III: Management
Bioavailability Study Design: Single Versus Multiple Dose Studies
Cholesterol: Significance and Regulation
Considering cholesterol and...
Bioequivalence of Drugs: Drugs with Multiple Indications
